Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6884912 | 0.86 | MCOLN3 (0.49) | POLBL3MBTL1KMT2AALDH1A1GAA | |
| SCHEMBL6764156 | 0.85 | ALDH1A1 (0.51) | POLBL3MBTL1KMT2AALDH1A1GAA | |
| SCHEMBL6762585 | 0.81 | DAGLA (0.45) | POLBGAADAGLAHTT | |
| SCHEMBL6764088 | 0.80 | USP2 (0.42) | POLBKMT2AALDH1A1DAGLAMAPT | |
| SCHEMBL6767003 | 0.79 | ALDH1A1 (0.50) | POLBL3MBTL1KMT2AALDH1A1GAA | |
| SCHEMBL4032633 | 0.79 | HTT (0.48) | L3MBTL1ALDH1A1GAADAGLAPKM | |
| SCHEMBL6762828 | 0.78 | ALDH1A1 (0.59) | POLBL3MBTL1KMT2AALDH1A1GAA | |
| SCHEMBL6763199 | 0.77 | BDKRB1 (0.57) | POLBL3MBTL1KMT2AALDH1A1TDP1 | |
| SCHEMBL11888773 | 0.76 | ALDH1A1 (0.52) | POLBL3MBTL1ALDH1A1GAADAGLA | |
| SCHEMBL6764091 | 0.75 | KEAP1 (0.53) | POLBALDH1A1GAAGLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| EP-1351928-A2 | NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER S.A. (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053516-A2 | N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER SA (FR) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | POLB 2689/4885L3MBTL1 2774/4885KMT2A 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.